A Review on an Evaluation of a Liposomal Hydrogel for Combined Minoxidil and Tretinoin Delivery in Androgenetic Alopecia

This critique examines a 2019 investigation by Kochar and colleagues, which engineered a liposomal hydrogel for the concurrent topical administration of Minoxidil (MXD) and Tretinoin (TRET) in addressing androgenetic alopecia (AGA). The foundational research offers a viable option beyond traditional formulations by utilizing liposomes to improve drug stability, encapsulation efficiency, and dermal compatibility, integrated with a hydrogel base to facilitate application and extend release duration. Although the investigation is methodically sound in its design, refinement, and preliminary ex vivo assessment, this analysis pinpoints notable shortcomings. These encompass the absence of in vivo effectiveness data within an alopecia model, inadequate exploration of the mechanistic interplay between MXD and TRET, and an incomplete stability evaluation. This review suggests specific remedial actions and prospective research avenues to address these deficiencies, promoting dedicated in vivo trials, sophisticated analytical methods for interaction analysis, and a more thorough stability-indicating protocol. The engineered system shows substantial promise, yet additional verification is necessary to transform this encouraging ex vivo outcomes into a viable clinical treatment.

Androgenetic Alopecia, Minoxidil, Tretinoin, Liposomes, Hydrogel, Topical Administration

1. Adil, A., & Godwin, M. (2017). The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis. Journal of the American Academy of Dermatology, 77(1), 136-141.e5. [Google Scholar] [Crossref]

2. Bhatia, N., Maisel, A., & Narda, M. (2014). A review of the etiopathogenesis and treatment of androgenetic alopecia in women. Journal of Drugs in Dermatology, 13(7), 791–796. [Google Scholar] [Crossref]

3. Blessy, M., Patel, R. D., Prajapati, P. N., & Agrawal, Y. K. (2014). Development of forced degradation and stability indicating studies of drugs—A review. Journal of Pharmaceutical Analysis, 4(3), 159–165. [Google Scholar] [Crossref]

4. Desai, P., & Patlolla, R. R. (2019). Interaction of nanoparticles with the skin and their delivery to hair follicles. Current Pharmaceutical Design, 25(37), 3930–3942. [Google Scholar] [Crossref]

5. Gupta, A. K., & Charrette, A. (2019). Efficacy of off-label topical treatments for the management of androgenetic alopecia: A review. Clinical Drug Investigation, 39, 233–239. [Google Scholar] [Crossref]

6. Hussain, A., Altamimi, M. A., Alshehri, S., & Imam, S. S. (2017). Liposomes for topical use: A physico-chemical comparison of vesicles prepared from egg or soy lecithin. Scientia Pharmaceutica, 85(3), 28. [Google Scholar] [Crossref]

7. Jones, D. S., Lorimer, C. P., & McCoy, C. P. (2019). Hydrogels: A promising platform for topical drug delivery and tissue engineering. International Journal of Pharmaceutics, 569, 118627.Kochar, P., Nayak, K., Thakkar, S., Polaka, S., Khunt, D., & Misra, M. (2019). Exploring the potential of minoxidil tretinoin liposomal based hydrogel for topical delivery in the treatment of androgenic alopecia. Cutaneous and Ocular Toxicology, 39(2), 43–53. [Google Scholar] [Crossref]

8. Mura, S., Pirot, F., Manconi, M., Falson, F., & Fadda, A. M. (2007). Liposomes and niosomes as potential carriers for dermal delivery of minoxidil. Journal of Drug Targeting, 15(2), 101–108. [Google Scholar] [Crossref]

9. Otberg, N., Finner, A. M., & Shapiro, J. (2007). Androgenetic alopecia. Endocrinology and Metabolism Clinics of North America, 36(2), 379–398. [Google Scholar] [Crossref]

10. Paus, R., & Cotsarelis, G. (1999). The biology of hair follicles. New England Journal of Medicine, 341(7), 491–497. [Google Scholar] [Crossref]

11. Rushton, D. H., Futterweit, W., & Kingsley, D. H. (2019). Topical minoxidil: Cardiac effects in baldness. The Journal of Clinical and Aesthetic Dermatology, 12(11), E53–E56. [Google Scholar] [Crossref]

12. Shin, H. S., Won, C. H., Lee, S. H., Kwon, O. S., Kim, K. H., & Eun, H. C. (2009). Efficacy of 5% minoxidil versus combined 5% minoxidil and 0.01% tretinoin for male pattern hair loss: A randomized, double-blind, comparative clinical trial. American Journal of Clinical Dermatology, 8(5), 285–290. [Google Scholar] [Crossref]

13. Suchonwanit, P., Thammarucha, S., & Leerunyakul, K. (2019). Minoxidil and its use in hair disorders: A review. Drug Design, Development and Therapy, 13, 2777–2786. [Google Scholar] [Crossref]

14. Sung, C. T., Juhasz, M. L., & Mesinkovska, N. A. (2019). The efficacy of topical minoxidil for non-scarring alopecia: A systematic review. Journal of Drugs in Dermatology, 18(2), 155–160. [Google Scholar] [Crossref]

15. Touitou, E., Dayan, N., Bergelson, L., Godin, B., & Eliaz, M. (2000). Ethosomes—novel vesicular carriers for enhanced delivery: Characterization and skin penetration properties. Journal of Controlled Release, 65(3), 403–418. [Google Scholar] [Crossref]

• QbD Approach to Hplc Method Development and Validation of the Simultaneous Estimation of Sulbactum and Durlobactum in Pharmaceutical Dosage Form